Preliminary results of 24-36 weeks of bedaquiline, delamanid, clofazimine and pyrazinamide for the treatment of MDR/RR-TB. - Vienna 2024

Tuberculosis treatment and management updates

Chair(s): Liga Kuksa, Olha Konstantynovska

Session type: Poster session

Preliminary results of 24-36 weeks of bedaquiline, delamanid, clofazimine and pyrazinamide for the treatment of MDR/RR-TB.

liu yidian

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Multidrug-resistant tuberculosis and treatment outcomes in Kazakhstan, Moldova, Ukraine, Georgia, and Kyrgyzstan

Dmytro Butov

Poster

Abstract

The effectiveness of pulmonary tuberculosis treatment during the COVID-19 pandemic

Ruzilya Usmanova

Poster

Abstract

Features of the BPaL triage routine practice algorithm in Bit-TB regions of Ukraine

Nataliia Lytvynenko

Poster

Abstract

Clinical features and prognosis of 206 children with pulmonary tuberculosis

Huimin Li

Poster

Abstract

Multidrug resistant tuberculosis (MDR-TB) incidence in close contacts of pulmonary MDR-TB index cases in East London - a retrospective study

Nicola Smallcombe

Poster

Abstract

The Prevalence of Polyneuropathy Among Patients with Drug-Resistant Tuberculosis and Concomitant Diabetes Mellitus. The Modifying Effect of Comorbidity on Tuberculosis Treatment Quality

Iryna Makoida

Poster

Abstract

Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multi-centre randomised controlled trial

Xiaolin Wei

Abstract

Impact of COVID-19 pandemic on clinical aspects of tuberculosis inpatients

Rita Vasconcelos Rodrigues Pereira

Poster

Abstract

Therapeutic outcomes of Bedaquiline containing oral regimens for Drug resistant tuberculosis

Vijay Kumar

Poster

Abstract

Rifampicin-resistant tuberculosis in Spain. Description of a patients cohort.

Jose Maria Garcia Garcia

Poster

Abstract

Hyponatremia and treatment outcomes in patients with tuberculosis

Hong-joon Shin

Poster

Abstract

Post-Bedaquiline era in Brazil: impact on adverse events and treatment outcomes.

Ana Paula Santos

Poster

Abstract

Preliminary results of 24-36 weeks of bedaquiline, delamanid, clofazimine and pyrazinamide for the treatment of MDR/RR-TB.

Liu Yidian

Poster

Abstract

Assessment of the effect of vitamin D levels in patients with pulmonary tuberculosis on the clinical course of the disease

Inga Yeremenchuk

Poster

Abstract

TB severity during COVID-19 pandemic in patients admitted in a tertiary clinic for lung diseases in Romania

Emilia Tabacu

Poster

Abstract

Multidrug-resistant tuberculosis and diabetes mellitus

Lilia Todoriko

Poster

Abstract

6- and 12-month follow-up results after successful BPaL treatment for DR-TB patients in Ukraine

Nataliia Lytvynenko

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}